BBS-Bioactive Bone Substitutes
Financials
Estimates*
EUR | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
---|---|---|---|---|---|---|---|
EBITDA | (<1m) | (1.2m) | <1m | (1.3m) | (2.4m) | (2.3m) | (2.7m) |
Profit | (<1m) | (4.4m) | <1m | (1.6m) | (2.7m) | (2.8m) | (3.1m) |
EV / EBITDA | - | - | 23.1x | -12.4x | -13.9x | -8.7x | -5.9x |
Source: Dealroom estimates
Date | Investors | Amount | Round |
---|---|---|---|
- | N/A | - | |
N/A | N/A | IPO | |
* | €500k | Post IPO Equity | |
Total Funding | - |
Recent News about BBS-Bioactive Bone Substitutes
EditBBS Bioactive Bone Substitutes Oyj is a pioneering company in the medical technology sector, specializing in the development of advanced bone graft substitutes. The company primarily serves orthopedic surgeons and hospitals, providing them with innovative solutions for bone healing and regeneration. Operating in the global healthcare market, BBS focuses on creating bioactive bone substitutes that are safer and more effective than traditional bone grafts. The company's flagship product is a bone healing paste that mimics the properties of natural bone, promoting faster and more reliable recovery for patients undergoing bone graft operations. BBS generates revenue through the sale of its proprietary bone graft products, leveraging its strong intellectual property portfolio, including patents granted in key markets like the USA. The company has also been recognized for its innovation, being nominated for the European Small and Mid Cap Awards 2020. With a growing market for bone grafts, estimated at nearly 3 million operations annually worldwide, BBS is well-positioned to capitalize on the increasing demand for advanced bone healing solutions.
Keywords: bone graft substitute, orthopedic, bioactive, bone healing, medical technology, innovation, patents, healthcare, recovery, global market.